Assembling a Fragment Library - Fragment-Based Drug Discovery - page 57

QC quality control

RCS reduced complexity screening

RECAP retrosynthetic combinatorial analysis procedure

rotB rotatable bonds

SAR structure-activity relationship

SMILES simplified molecular input line entry specification

TPSA topological polar surface area

uHTS ultra-high-throughput screening

VS virtual screening

3.7 Acknowledgements

The authors wish to thank John Barker, Oliver Barker and Thomas Hesterkamp for their
contributions to the fragment-based drug discovery initiative at Evotec and for useful
discussions.

References

[1] C.W. Murray, O. Callaghan, G. Chessari, A. Cleasby, M. Congreve, M. Frederickson,
M.J. Hartshorn, R. McMenamin, S. Patel and N. Wallis, Application of fragment screening
by X-ray crystallography to -secretase, J. Med. Chem ., 50 , 1116-1123 (2007).
[2] M. Congreve, D. Aharony, J. Albert, O. Callaghan, J. Campbell, R.A.E. Carr, G. Chessari,
S. Cowan, P.D. Edwards, M. Frederickson, R. McMenamin, C.W. Murray, S. Patel andN.Wallis,
Application of fragment screening by X-ray crystallography to the discovery of aminopyridines
as inhibitors of -secretase, J. Med. Chem ., 50 , 1124-1132 (2007).
[3] A.L. Hopkins, C.R. Groom, and A. Alex, Ligand efficiency: a useful metric for lead selection,
Drug Discov. Today , 9 , 430-431 (2004).
[4] C. Abad-Zapatero and J.T. Metz, Ligand efficiency indices as guideposts for drug discovery,
Drug Discov. Today , 10 , 430-431 (2005).
[5] I.D. Kuntz, K. Chen, K.A. Sharp and P.A. Kollman, The maximal affinity of ligands, Proc. Natl.
Acad. Sci. USA , 96 , 9997-10002 (1999).
[6] C.A. Lipinski, F. Lombardo, B.W. Dominy and P.J. Feeney, Experimental and computational
approaches to estimate solubility and permeability in drug discovery and development settings,
Adv. Drug Deliv. Rev ., 23 , 3-25 (1997).
[7] M. Congreve, R. Carr, C. Murray and H. Jhoti: A 'Rule of Three' for fragment-based lead
discovery, Drug Discov. Today , 8 , 876-877 (2003).
[8] A.-D. Gorse, Diversity in medicinal chemistry space, Curr. Top. Med. Chem ., 6 , 3-18 (2006).
[9] T. Fink, H. Bruggesser and J.-L. Reymond, Virtual exploration of the small-molecule chemical
universe below 160 daltons, Angew. Chem. Int. Ed ., 44 , 1504-1508 (2005).
[10] T. Fink and J.-L. Reymond, Virtual exploration of the chemical universe up to 11 atoms of C, N,
O, F: assembly of 26.4 million structures (110.9 million stereoisomers) and analysis for new ring
systems, stereochemistry, physicochemical properties, compound classes, and drug discovery,
J. Chem. Inf. Model ., 47 , 342-353 (2007).
[11] R.S. Bohacek, C. Martin and W.C. Guida, The art and practice of structure-based drug design:
a molecular modelling approach, Med. Res. Rev ., 16 , 3-50 (1996).
[12] M.M. Hann, A.R. Leach and G. Harper, Molecular complexity and its impact on the probability
of finding leads for drug discovery, J. Chem. Inf. Comput. Sci ., 41 , 856-864 (2001).